Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity

B Barbara Kronsteiner (NDM Centre for Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom) M Melissa Govender C Chang Liu A Aiste Dijokaite-Guraliuc M Mohammad Ali J Jennifer Hill M Martha Zewdie A Andrew Cross J James Austin A Amyleigh Watts A Adrienn Angyal H Hailey Hornsby P Priyanka Abraham S Sandra Adele S Srija Moulik J Jodie Harte A Alexander Hargreaves Y Yasmin Jiwa M Muneeswaran Selvaraj L Lizzie Stafford A Anni Jamsen S Susan L. Dobson S Sofia Sampaio C Callum Halstead A Amy Steel S Stephanie Longet S Siân E. Faustini (Clinical Immunology Services, University of Birmingham, Birmingham, United Kingdom) S Shona C. Moore J Juthathip Mongkolsapaya D Daniel G. Wootton J James E. D. Thaventhiran S Susan Hopkins V Victoria Hall K Katie Jeffery E Eleanor Barnes C Christopher J. A. Duncan R Rebecca P. Payne A Alex G. Richter T Thushan I. de Silva L Lance Turtle (Institute of Infection, Ecological and Veterinary Sciences, University of Liverpool & Liverpool University Hospital National Health Service Foundation Trust) G Gavin R. Screaton P Paul Klenerman (Translational Gastroenterology and Liver Unit, University of Oxford, Oxford, United Kingdom) M Miles Carroll S Susanna J. Dunachie

Abstract

Abstract COVID-19 vaccines were updated to address immune escape from variants of concern (VOC). We explored the impact of ancestral/BA.1 bivalent mRNA booster vaccination (Autumn 2022) on peripheral and nasal antibody and T-cell responses to SARS-CoV-2 in an observational cohort of 133 healthcare workers, building on previous longitudinal vaccination studies. We demonstrate that maintenance of antibody and T-cell responses up to eighteen months following the third vaccine is at least partially driven by intercurrent infection. Boosting with the bivalent vaccine increases the breadth of circulating and nasal antibodies to spike, which waned over time but was still detectable six months post-dose. T-cell responses are well maintained and highly cross-reactive to VOCs irrespective of booster vaccination. Vaccination strongly boosted nasal IgG, but this was short-lived compared to circulating antibodies. Overall, ongoing COVID-19 vaccination provides benefit, boosting immunity in individuals who have not been recently infected, but new strategies may be needed to provide longer-term nasal immunity.

Article Details

Volume / Issue Vol. 15, Issue 1
Published November 27, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (44)

B

Barbara Kronsteiner

NDM Centre for Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

M

Melissa Govender

C

Chang Liu

A

Aiste Dijokaite-Guraliuc

M

Mohammad Ali

J

Jennifer Hill

M

Martha Zewdie

A

Andrew Cross

J

James Austin

A

Amyleigh Watts

A

Adrienn Angyal

H

Hailey Hornsby

P

Priyanka Abraham

S

Sandra Adele

S

Srija Moulik

J

Jodie Harte

A

Alexander Hargreaves

Y

Yasmin Jiwa

M

Muneeswaran Selvaraj

L

Lizzie Stafford

A

Anni Jamsen

S

Susan L. Dobson

S

Sofia Sampaio

C

Callum Halstead

A

Amy Steel

S

Stephanie Longet

S

Siân E. Faustini

Clinical Immunology Services, University of Birmingham, Birmingham, United Kingdom

S

Shona C. Moore

J

Juthathip Mongkolsapaya

D

Daniel G. Wootton

J

James E. D. Thaventhiran

S

Susan Hopkins

V

Victoria Hall

K

Katie Jeffery

E

Eleanor Barnes

C

Christopher J. A. Duncan

R

Rebecca P. Payne

A

Alex G. Richter

T

Thushan I. de Silva

L

Lance Turtle

Institute of Infection, Ecological and Veterinary Sciences, University of Liverpool & Liverpool University Hospital National Health Service Foundation Trust

G

Gavin R. Screaton

P

Paul Klenerman

Translational Gastroenterology and Liver Unit, University of Oxford, Oxford, United Kingdom

M

Miles Carroll

S

Susanna J. Dunachie